{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:32:44Z","timestamp":1789637564104,"version":"4.0.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jhep.2016.05.009","type":"journal-article","created":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T20:32:58Z","timestamp":1463517178000},"page":"601-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial"],"prefix":"10.1016","volume":"65","author":[{"given":"Hedwig M.A.","family":"D\u2019Agnolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wietske","family":"Kievit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Bart","family":"Takkenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Ria\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Bujanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrte K.","family":"Neijenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen J.L.","family":"Brunenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Beuers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus M.","family":"Banales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P.H.","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.05.009_b0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrgastro.2012.254","article-title":"Diagnosis and management of polycystic liver disease","volume":"10","author":"Gevers","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.05.009_b0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2215\/CJN.00080605","article-title":"Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort","volume":"1","author":"Bae","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2016.05.009_b0015","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/liv.12430","article-title":"Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume","volume":"34","author":"Wijnands","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.05.009_b0020","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1478-3231.2007.01595.x","article-title":"Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease","volume":"28","author":"Hoevenaren","year":"2008","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.05.009_b0025","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/hep.24036","article-title":"Medical and surgical treatment options for polycystic liver disease","volume":"52","author":"Drenth","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.009_b0030","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2215\/CJN.05380709","article-title":"Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide","volume":"5","author":"Caroli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2016.05.009_b0035","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/liv.12726","article-title":"Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial","volume":"35","author":"Gevers","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.05.009_b0040","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The long-term outcome of patients with polycystic liver disease treated with lanreotide","volume":"35","author":"Chrispijn","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.05.009_b0045","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1073\/pnas.1309438111","article-title":"Whole-exome sequencing reveals LRP5 mutations and canonical Wnt signaling associated with hepatic cystogenesis","volume":"111","author":"Cnossen","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2016.05.009_b0050","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrgastro.2014.155","article-title":"Polycystic liver diseases: advanced insights into the molecular mechanisms","volume":"11","author":"Perugorria","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.05.009_b0055","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/hep.22636","article-title":"The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD)","volume":"49","author":"Banales","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.009_b0060","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1172\/JCI72272","article-title":"Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease","volume":"124","author":"Harris","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2016.05.009_b0065","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2032,5\u2032-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.05.009_b0070","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1172\/JCI116921","article-title":"Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis","volume":"92","author":"Beuers","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2016.05.009_b0075","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2353\/ajpath.2006.050126","article-title":"Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts","volume":"168","author":"Marzioni","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2016.05.009_b0080","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2353\/ajpath.2008.080125","article-title":"Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease","volume":"173","author":"Banales","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2016.05.009_b0085","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2015.05.023","article-title":"Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease","volume":"63","author":"Munoz-Garrido","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.009_b0090","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1046\/j.1365-2036.2003.01792.x","article-title":"Systematic review: ursodeoxycholic acid\u2013adverse effects and drug interactions","volume":"18","author":"Hempfling","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.05.009_b0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2016.05.009_b0100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2013.03.004","article-title":"Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial","volume":"59","author":"Chrispijn","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.009_b0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2369-13-17","article-title":"Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease","volume":"13","author":"Gevers","year":"2012","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jhep.2016.05.009_b0110","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.jhep.2016.05.009_b0115","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1109\/34.56205","article-title":"Scalespace and edge detection using anisotropic diffusion","volume":"12","author":"Perona","year":"1990","journal-title":"IEEE Trans Pattern Anal Mach Intell"},{"key":"10.1016\/j.jhep.2016.05.009_b0120","doi-asserted-by":"crossref","unstructured":"N O. A threshold selection method from gray-level histogram. IEEE Transactions on SMC 8 1978:62\u201366.","DOI":"10.1109\/TSMC.1979.4310076"},{"key":"10.1016\/j.jhep.2016.05.009_b0125","doi-asserted-by":"crossref","DOI":"10.1002\/hep.28545","article-title":"Development and validation of a disease-specific questionnaire to assess patient-reported symptoms in polycystic liver disease","author":"Neijenhuis","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.009_b0130","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0140-6736(09)60070-2","article-title":"Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial","volume":"373","author":"van Marrewijk","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.05.009_b0135","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s10620-006-9120-6","article-title":"Evaluation of a gastrointestinal symptoms questionnaire","volume":"51","author":"Bovenschen","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2016.05.009_b0140","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.05.009_b0145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/1744-9987.12326","article-title":"Ursodeoxycholic acid for treatment of enlarged polycystic liver","volume":"20","author":"Iijima","year":"2016","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jhep.2016.05.009_b0150","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ncpgasthep0521","article-title":"Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis","volume":"3","author":"Beuers","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.05.009_b0155","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1136\/gutjnl-2013-305281","article-title":"Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases","volume":"63","author":"Urribarri","year":"2014","journal-title":"Gut"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816301957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816301957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T15:39:46Z","timestamp":1567870786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816301957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0168827816301957"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.05.009","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}